JP7142022B2 - Malt1の阻害剤およびそれらの使用 - Google Patents

Malt1の阻害剤およびそれらの使用 Download PDF

Info

Publication number
JP7142022B2
JP7142022B2 JP2019549411A JP2019549411A JP7142022B2 JP 7142022 B2 JP7142022 B2 JP 7142022B2 JP 2019549411 A JP2019549411 A JP 2019549411A JP 2019549411 A JP2019549411 A JP 2019549411A JP 7142022 B2 JP7142022 B2 JP 7142022B2
Authority
JP
Japan
Prior art keywords
alkyl
unsubstituted
substituted
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511454A5 (cg-RX-API-DMAC10.html
JP2020511454A (ja
Inventor
グレイ,ナタナエル,エス.
スコット,デイビッド,エー.
ハッチャー,ジョン
メルニック,アリ,エム.
ギャバス,ロレーナ,フォンタン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2020511454A publication Critical patent/JP2020511454A/ja
Publication of JP2020511454A5 publication Critical patent/JP2020511454A5/ja
Application granted granted Critical
Publication of JP7142022B2 publication Critical patent/JP7142022B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019549411A 2017-03-08 2018-03-08 Malt1の阻害剤およびそれらの使用 Active JP7142022B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762468758P 2017-03-08 2017-03-08
US62/468,758 2017-03-08
US201762553336P 2017-09-01 2017-09-01
US62/553,336 2017-09-01
PCT/US2018/021481 WO2018165385A1 (en) 2017-03-08 2018-03-08 Inhibitors of malt1 and uses thereof

Publications (3)

Publication Number Publication Date
JP2020511454A JP2020511454A (ja) 2020-04-16
JP2020511454A5 JP2020511454A5 (cg-RX-API-DMAC10.html) 2021-04-15
JP7142022B2 true JP7142022B2 (ja) 2022-09-26

Family

ID=63448912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549411A Active JP7142022B2 (ja) 2017-03-08 2018-03-08 Malt1の阻害剤およびそれらの使用

Country Status (4)

Country Link
US (1) US11248007B2 (cg-RX-API-DMAC10.html)
EP (1) EP3592731A4 (cg-RX-API-DMAC10.html)
JP (1) JP7142022B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018165385A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3736277A1 (en) * 2016-07-29 2020-11-11 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018020474A1 (en) * 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
BR112021009994A2 (pt) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento
KR102982241B1 (ko) * 2019-03-12 2026-06-25 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 자가항체 검출용 조성물, 키트, 및 방법
US12404260B2 (en) * 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
TW202115077A (zh) * 2019-07-01 2021-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Malt1抑制劑及其用途
EP4163280A4 (en) * 2020-05-27 2024-06-05 Takeda Pharmaceutical Company Limited METHOD FOR PRODUCING A HETEROCYCLIC COMPOUND
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス,インコーポレーテッド がんを治療する材料及び方法
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
JP2026510946A (ja) * 2023-03-17 2026-04-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア レチンアルデヒドデヒドロゲナーゼ1(raldh1)阻害剤および免疫賦活剤の組み合わせならびにそれらの使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
JP2015536990A (ja) 2012-11-09 2015-12-24 コーネル・ユニバーシティーCornell University Malt1の低分子阻害剤
JP2019522035A (ja) 2016-07-29 2019-08-08 ルピン・リミテッド Malt1阻害剤としての置換チアゾロ−ピリジン化合物
JP2019537599A (ja) 2016-11-01 2019-12-26 コーネル ユニバーシティー Malt1分解のための化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
GB2504550A (en) 2012-08-03 2014-02-05 Nanyang Polytechnic Diarylurea compound PQ401 for inhibiting the growth and/or proliferation of cancer stem cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
JP2015536990A (ja) 2012-11-09 2015-12-24 コーネル・ユニバーシティーCornell University Malt1の低分子阻害剤
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
WO2015181747A1 (en) 2014-05-28 2015-12-03 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
JP2019522035A (ja) 2016-07-29 2019-08-08 ルピン・リミテッド Malt1阻害剤としての置換チアゾロ−ピリジン化合物
JP2019537599A (ja) 2016-11-01 2019-12-26 コーネル ユニバーシティー Malt1分解のための化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Chemical Information and Modeling,2011年,Vol. 51, No. 6,pp. 1474-1491

Also Published As

Publication number Publication date
EP3592731A4 (en) 2020-10-07
EP3592731A1 (en) 2020-01-15
WO2018165385A1 (en) 2018-09-13
JP2020511454A (ja) 2020-04-16
US11248007B2 (en) 2022-02-15
US20200385405A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
JP7097880B2 (ja) Malt1分解のための化合物
US11248007B2 (en) Inhibitors of MALT1 and uses thereof
JP7258748B2 (ja) サイクリン依存性キナーゼ12(cdk12)の阻害剤およびその使用
JP7308146B2 (ja) インターロイキン1受容体関連キナーゼの阻害剤およびその使用
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP7785108B2 (ja) 血漿カリクレインの阻害剤およびその使用
EP3876939A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP7675070B2 (ja) 治療、特にmyd88変異疾患における使用のためのhck阻害剤としてのピラゾロピリミジン誘導体
EP4377306A1 (en) Rock2 inhibitors and uses thereof
US12590084B2 (en) Oxadiazole HDAC6 inhibitors and uses thereof
JP2025539828A (ja) Ripk2の阻害剤及びその医学的使用
JP7185631B2 (ja) 抗線維化化合物
JP2019505548A (ja) Mycモジュレーターとしてのmaxバインダーおよびこれらの使用
WO2023150203A1 (en) Hdac6 inhibitors and uses thereof
EA052549B1 (ru) Ингибиторы rock2 и их применение
CN118055926A (zh) Rock2抑制剂及其用途
WO2017218874A1 (en) Hedgehog acyltransferase inhibitors and uses thereof
CA2972239A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220912

R150 Certificate of patent or registration of utility model

Ref document number: 7142022

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250